Affimed NV Corporate Call Transcript
Good afternoon, everyone, and welcome to Affimed's investor event to discuss our announcement today and the development of AFM13, our CD30-positive new lymphoma targeting Innate Cell Engager at the 64th American Society of Hematology Annual Meeting and Exposition. I'm Alex Fudukidis, Head of Investor Relations at Affimed. As a reminder, today's webcast is being recorded and the recording will be made available on our website later today.
Before we begin, I'd like to remind everyone that we issued 2 press releases earlier this afternoon, 1 about our REDIRECT study, the monotherapy study of AFM13 in relapsed refractory PTCL patients and the other about the investigator-sponsored trial of AFM13 in combination with cord blood-derived natural killer cells in CD positive Hodgkin's and non-Hodgkin's lymphoma patients. Both press releases may be found on the Investor Relations section of our website. On our site, you will also find the presentation which we'll be sharing with you today.
Today, we have the following members of our management team
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
